{"name":"Repros Therapeutics Inc.","slug":"repros-therapeutics-inc","ticker":"","exchange":"","domain":"reprosrx.com","description":"","hq":"The Woodlands","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"CYP2C19 probe","genericName":"CYP2C19 probe","slug":"cyp2c19-probe","indication":"Other","status":"phase_1"},{"name":"Placebo Capsules","genericName":"Placebo Capsules","slug":"placebo-capsules","indication":"Clinical trial control comparator","status":"marketed"},{"name":"AndroGel 1.62%","genericName":"AndroGel 1.62%","slug":"androgel-1-62","indication":"Testosterone replacement therapy in adult males with hypogonadism","status":"marketed"},{"name":"Androxal","genericName":"Androxal","slug":"androxal","indication":"Other","status":"phase_3"},{"name":"Androxal 25 mg","genericName":"Androxal 25 mg","slug":"androxal-25-mg","indication":"Other","status":"phase_1"},{"name":"Androxal 250 Capsules","genericName":"Androxal 250 Capsules","slug":"androxal-250-capsules","indication":"Other","status":"phase_1"},{"name":"Lucron Depot","genericName":"Lucron Depot","slug":"lucron-depot","indication":"Other","status":"phase_1"},{"name":"Proellex","genericName":"Proellex","slug":"proellex","indication":"Other","status":"discontinued"},{"name":"Progenta","genericName":"Progenta","slug":"progenta","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"CYP2C19 probe","genericName":"CYP2C19 probe","slug":"cyp2c19-probe","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo Capsules","genericName":"Placebo Capsules","slug":"placebo-capsules","phase":"marketed","mechanism":"Placebo capsules contain no active pharmaceutical ingredient and produce therapeutic effects primarily through the placebo effect.","indications":["Clinical trial control comparator","Conditions responsive to placebo effect"],"catalyst":""},{"name":"AndroGel 1.62%","genericName":"AndroGel 1.62%","slug":"androgel-1-62","phase":"marketed","mechanism":"AndroGel 1.62% is a testosterone replacement therapy that restores physiological testosterone levels in hypogonadal men.","indications":["Testosterone replacement therapy in adult males with hypogonadism"],"catalyst":""},{"name":"Androxal","genericName":"Androxal","slug":"androxal","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Androxal 25 mg","genericName":"Androxal 25 mg","slug":"androxal-25-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Androxal 250 Capsules","genericName":"Androxal 250 Capsules","slug":"androxal-250-capsules","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Lucron Depot","genericName":"Lucron Depot","slug":"lucron-depot","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Proellex","genericName":"Proellex","slug":"proellex","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Progenta","genericName":"Progenta","slug":"progenta","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxQSFBPQ3NxTzJvT0tZS21oUWtXMjV3eWI4UjlfckZaY3ZYY2ZORHhoVWhRWHJnZXlKSkdGa012NmZKQ2N0SWNoUTlZeEx3SzJod2FzQmhqSkdkQVpLS2ZNM3BlWTBwVlZxalp4MzlkSWs0dktZMTEzRjMzZ0pOaVlCZzVlajBZN1l1RTM4RUR1OXFsNHE3aXZXZWZub3hncW4xS1NSMGZUSEMxQUNhcmhmQ0EzNlhNNEJ3OEQ4OVNFQUVwc3lhb0dQX21sUjNfSE1wUC1mSXN6QkJ5SUFvOVhfN0hJOUtxeFQwZW9GdW9RaF9ielpaV0R4UkhmcF9CSXd1UEpLUk50eFQ2RWttZlR3?oc=5","date":"2026-03-13","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and REPRO-MED Systems (KRMD) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and REPRO-MED Systems (KRMD)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxPdlpvVEk4VUxxYkhjMnVVSExfZE95MloyZHQ5NmFjd2NjQUhZUV9qX05Da2U1THZLcmJiTmhhSXVPVWFoYTktRHBWZldpVDJUalEzSUVfdWtfT2xkU0hNZ1QyU21QRDJrUWJYNGllRks3S29vM1kwZHBXbjI3QnFIdS12bjNjQWQ0YUdKdTQyeEZ2aE03dnRab2ItcTlkU21kdWozcExqLVBmNVl6VFNDUHI1Z1lDVFJqT3JZbS04WFd5ZUM4eEFFazJFUzl0S2JQSzdQcEhiR2tZNWNmNjVNNXFtbWJSOVE4NFBnUG5aSnBtbl9GMFNDQV9KMXFXXzNXS0J0VUpZaw?oc=5","date":"2026-03-10","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on Top Healthcare Stocks: MBX Biosciences, Inc. (MBX), REPRO-MED Systems (KRMD) - The Globe and Mail","headline":"Analysts Are Bullish on Top Healthcare Stocks: MBX Biosciences, Inc. (MBX), REPRO-MED Systems (KRMD)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxPZWJueVpKWXNhWmtQTlJzRHlISGJZZGc0SndJR0lSRWUyNzRXT0FnclJwMTNtNkdncFJGazBLaGhfSE9vUHZJUkdDSFRZMG9CQ2w1YnJWOG5KTTFTc19KQWc1WWs0RTRPODY2TUZnSzdmLW5JSzlzVnZxMk9xeEtpVlIzaG5FNkZKTzZKTzN1TzRWVjY4amhmXzNYdENKR19wMk01UFU4NWdjS1VOMlpDZTcxVUJLSjYtV3pXb254RmlWVDctVnpJVk1IakpYb19aTWpIZnNScHhkZVM2SzRkRmt1YkdWTUJZWnloLTIta2VFTUZoNHJ5Ug?oc=5","date":"2025-08-13","type":"pipeline","source":"prnewswire.com","summary":"GnRH Antagonists Market on Upward Trajectory During the Forecast Period (2025-2034) Across the 7MM | DelveInsight - prnewswire.com","headline":"GnRH Antagonists Market on Upward Trajectory During the Forecast Period (2025-2034) Across the 7MM | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOTmh0QmRDV191eURiTnFkS082NkpySXh3MUJJTXVCVzBIc3UwTEs2b3gzcGhvRm1BbWdYQTgxck9wN0dJc05mSVEtaDBKRWJWdmJMYU9GQzNxMlg4VUl1ZElOZWRQTGxjOHNQRWhyTGVlODg1NDNwM1VySFFpa2psbjVuRkJ3THZ4Qkp0aUlMV0dzWFhBbjhsM1hBd3B1OHljNHZwNDhxOFlCNmRTMHUwZ01mUmpTcnVXUW90b0tB?oc=5","date":"2024-08-15","type":"pipeline","source":"24-7 Press Release Newswire","summary":"Marquis Who's Who Honors Nola E. Masterson for Expertise in Investing - 24-7 Press Release Newswire","headline":"Marquis Who's Who Honors Nola E. Masterson for Expertise in Investing - 24-7 Press Release Newswire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPMjctYmpoLTdoZG5Zc3BoV0w3YVZfS2pwN0lOOWNnR0ZZTzV5ekJRaGdKYVdpZXhNQ3RZb05QVG9rU3NNRXl0WEY4YWF6TU5mQmctQ3llazZOTElrN0RGZDZhT1lpVWtLRUttVmxPM1FJR3ViOG52ajVSZTBwZ3RFcV9WUUFXOEJ1QXliTnllbGxHOEE?oc=5","date":"2024-06-21","type":"pipeline","source":"SEC.gov","summary":"abbv-20221231xex21.htm - SEC.gov","headline":"abbv-20221231xex21.htm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOM0YyQTY5REhYZklMejJlRlN4X3RBODdyd2hDaGRaeXpDUjZPV1FNYmlYN1BKRTdSQ1hMUFhrSFRWZ21neUZyN1lkTW01Zlo3c2ZIWV9BcnMxNk5xbzAtTzB2Z1JIb2RXMHJEQTVTRWlJMTl5bjNERlVVYlZqVG9adTUxV09wWHBZa3ZZMkRxUGFvTVpSelpMTXAtVEo5OFlVd1VudEhtbTk?oc=5","date":"2018-01-25","type":"pipeline","source":"Fierce Biotech","summary":"British newco KaNDy Therapeutics said to be in Allergan M&A crosshairs - Fierce Biotech","headline":"British newco KaNDy Therapeutics said to be in Allergan M&A crosshairs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxObkJzcTdzaUF0MjZDZ2x5MklfU2dqd01mZUJQbkRkVGxzdFhjaGZWUVZBOWFuaWlVM25xTURIQ1dkRnRWczliSWJ0bkpDQjJzZUdzc1JMS0Viems0REx6a01iT3RNRlZOYzRCQXVtVUxXRlVqNFZWREM2a2xBODVXekhDb2duZjdENWgybGhzQmR6NmpYX2luSG5mVWJTbV9ydVBNanhsQ05hQllXVWlRVXNmTWVCdFlISlY3QVRmUFVWbjJFV2laTk9uX2VBdw?oc=5","date":"2017-12-12","type":"pipeline","source":"GlobeNewswire","summary":"Repros Therapeutics Inc.® Announces Acquisition by Allergan plc - GlobeNewswire","headline":"Repros Therapeutics Inc.® Announces Acquisition by Allergan plc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNRzhXUW9XSjhDSWdwcEhITEVNS0RxWDB2aHlKc1pMMC1EWms0UlBBUG92S0FWZ0Q4M3JGOVM3NXY2bDJhcXlKdjdQaXZKdmJ4SWUzVEt1WHNiUjRMZlRCdlZTVHlGWGtaSDJxR1NUWC0tdTU1YmpZakNqdVgyWVkwOHJ1eFVLWENZUl9yVGYtRHR0cS1IZ3B1S0Fxd1RSTGNmWl9F?oc=5","date":"2017-12-12","type":"deal","source":"The Business Journals","summary":"Allergan to buy Woodlands-based drug company - The Business Journals","headline":"Allergan to buy Woodlands-based drug company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQMTdMQmZJRXBDUTRVYUdaMTlyUnVxWUhZUlNwMzV0Rko4dUlGM2NlWlpQQ09QdjdlWldDaVRMeU42YzRoN0RHUjJIcXp3OWluQ1F5V3RMZXBVVGNyY1hwNTRwNTZFSnBfU3B0SkxRcHJtUm9oTFk2QzB6c1diMEhFUnlRelBPMGFKZGc?oc=5","date":"2017-07-17","type":"pipeline","source":"BioPharma Dive","summary":"Clinical hold still in effect for Repros’ oral drug - BioPharma Dive","headline":"Clinical hold still in effect for Repros’ oral drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxNenBzbmN1bl9QYTJQVGdOSE1XQnhGM2VYV2drV1RfWGJmZ1hrV3ZhOFVpX0gtb3Z5S1JmRzlDVUF1ZFo2d2xTRFd5TUhVZTB1cjdxd2hjVzA5U3RPano3OERlX1RoVmpDYVkwODhFRDJseklSRi00c3lSMTJjQ2hpS2M5ZFpVbjJVRC1YcG84VWNINklVdUNUS0RldlVmYlZLRlRjS1hVQWdmTEFXZzRiM1UyNEE4SnpuRS1uaUVZbUJrVnZlVkdPMGc3ZU5leEF6ZWRKVHRveWptVUNBcWc5ZWh3Nmt0Y2cxZFQyLUJCb3pGSW9kZl96S2V3R3kteEQ5c1pCVldKQ0pCLXpMcmdkUURR?oc=5","date":"2017-05-18","type":"pipeline","source":"GlobeNewswire","summary":"Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock - GlobeNewswire","headline":"Repros Announces Pricing of $3.0 Million Public Offering Of Common Stock And Warrants To Purchase Common Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPb3VVSWRwV0c2WkwyeE5yNGFnRGlMSDFjaWlXQkxYVGswRWNscmt6bFZJSHluMlRsTEpSNTR4UFVjdlV1dEhIT05ZNXhvT05NODE0ZFZJcThNLXpwQVFYSEpwUk9FSktlczQyRXdzNlRNVUZWV2w3NWVDdGdhMG1XLWM0M21YTmxG?oc=5","date":"2016-09-27","type":"regulatory","source":"BioPharma Dive","summary":"Repros gets another shot at FDA adcomm - BioPharma Dive","headline":"Repros gets another shot at FDA adcomm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPZkl0ZHRBaXZzMUFQLVJrMUlfZ2YwVy16MlBRdFVyWkdhQ0dCQVZHUllDZHV1TTNlRWZxX1BFVUFabTJyN1puVnIwV2V3VjNUbGpTbVl4NzhaZ1RJcUIycTlJZTRRU09WR084N242b3RLbmRUbVBiNUNJREhLdEFrN3NUN1Btb3p1elI2Z215QS1jbk5Xc1JOYklGWFk1Yy1XLVdhNWN0ZkpqcHdW?oc=5","date":"2015-10-30","type":"regulatory","source":"BioSpace","summary":"Repros Therapeutics Stock Plunges as FDA Advisory Panel Cancels Enclomiphene Review - BioSpace","headline":"Repros Therapeutics Stock Plunges as FDA Advisory Panel Cancels Enclomiphene Review","sentiment":"neutral"}],"patents":[],"drugCount":9,"phaseCounts":{"phase_1":5,"marketed":2,"phase_3":1,"discontinued":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}